Post-Marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ozempic®

Novo Nordisk A/S3,217 enrolled

Overview

The purpose of this study is to assess the safety of long-term treatment with Ozempic® in patients with type 2 diabetes mellitus. People will get Ozempic® as prescribed by their doctor. People will be in this study about 3 years. People above the age of 18 will be asked to fill in the quality of life (QOL) questionnaire (the QOL questionnaire is for the assessment of the influence of diabetes treatment on people's life). There is a possibility that people's blood sample would be provided to Novo Nordisk from their doctors in case of severe allergic reaction that might be caused by Ozempic®.

Study Type

OBSERVATIONAL

Enrollment

3,217

Conditions

Diabetes Mellitus, Type 2

Interventions

semaglutideDRUG

Patients will be treated with commercially available Ozempic® according to routine clinical practice at the discretion of the treating physician. The treating physician's decision to initiate treatment with Ozempic® is independent of the decision to include the patient in the study.

Eligibility

Medical Language ↔ Plain English

Inclusion Criteria: * Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). * The decision to initiate treatment with commercially available Ozempic® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study. * Patients with Diabetes Mellitus, Type 2 (T2DM) who the physician has decided to start treatment with Ozempic®. * Male or female, no age limitation. Exclusion Criteria: * Previous participation in this study. Participation is defined as having given informed consent in this study. * Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation. * Patients who fall under contraindications to the label. * Patients who are or have previously been treated with Ozempic®. * Female who is pregnant, breast-feeding or intends to become pregnant.

Locations (414)

Seino Internal Medicine Clinic_Internal medicine

Koriyama-shi, Fukushima, Fukushima, Japan, Japan

Tsuruma Kaneshiro Diabetes Clinic_Internal medicine

Yamato-shi, Kanagawa, Japan

Takai Internal Medicine Clinic_Internal Medicine

Kamakura-shi, Kanagawa, Kanagawa, Japan, Japan

Matsuba Clinic_Internal Medicine

Kawasaki-shi, Kanagawa, Japan, Japan

Jinnouchi Hospital_Internal Medicine

Kumamoto, Kumamoto, Japan, Japan